|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EB04
|
|
gptkbp:blackBoxWarning
|
no
|
|
gptkbp:brand
|
gptkb:Tagrisso
|
|
gptkbp:CASNumber
|
1421373-65-0
|
|
gptkbp:category
|
protease inhibitor
antineoplastic agent
orphan drug
|
|
gptkbp:chemicalClass
|
quinazoline derivative
|
|
gptkbp:countryOfOrigin
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:discoveredBy
|
gptkb:AstraZeneca
|
|
gptkbp:eliminationHalfLife
|
48 hours
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericName
|
gptkb:osimertinib
gptkb:osimertinib_mesylate
|
|
gptkbp:hasInChIKey
|
YQEZLKZALYSWHR-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C28H33N7O2
|
|
gptkbp:hasSMILES
|
COc1cccc2c1N(C(=O)N(C2=O)C)CC3=NC4=CC=CC=C4N3C5CCN(CC5)C
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tagrisso
|
|
gptkbp:indication
|
gptkb:EGFR_mutation-positive_NSCLC
locally advanced non-small cell lung cancer
metastatic non-small cell lung cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:EGFR_tyrosine_kinase_inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A5
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
499.61 g/mol
|
|
gptkbp:patentExpired
|
2032 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:prescribes
|
adults
patients with EGFR T790M mutation-positive NSCLC
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
rash
QT prolongation
interstitial lung disease
dry skin
nail toxicity
stomatitis
|
|
gptkbp:target
|
gptkb:EGFR_T790M_mutation
|
|
gptkbp:bfsParent
|
gptkb:AstraZeneca
|
|
gptkbp:bfsLayer
|
5
|